Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Comparison of BAY94-9027 and Elocta in Severe Hemophilia A
NCT03364998Phase 1Completed
- Sponsor
- Bayer
- Start
- Nov 2017
- Primary completion
- Jan 2018
- Modality
- Polymer-based Nanoparticles, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of damoctocog alfa pegol in hemophilia A (2 arms), sponsored by Bayer. Primary endpoint: Area Under the Curve from time 0 to the last data point. Started Nov 2017; status: completed.
02
Drugs
damoctocog alfa pegol
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT03364998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03364998.